Fantastic work to get this happening 🙌🏾🙌🏾🙌🏾

It’s in the paper. Median follow up time from randomisation was 44.2 months in Osi arm and 19.1 months in placebo. Median follow up post Osi was 11.7months

My concern with this is that CNS was a common site of recurrence and there is morbidity and mortality associated. Nuanced discussion with patient re: toxicity vs waiting. I suspect most of my pts would take Osi, but close surveillance also very reasonable.

Random chance from small numbers. But note that baseline is post surgery +/- chemo. More likely MRD+ if higher stage and also MRD+ effectively is St4, as on cessation of Osi, all MRD+ recurred

I think these data highlight the relevance of MRD assays in guiding treatment decisions esp in oncogene driven tumours. This may mean longer duration of therapy though.

MRD RaDaR assay was 65% sensitive and 95% specific. The co-mutation data are also interesting. TP53 seems to also be associated with poorer outcomes in early stage disease #NSCLC #Earlystage @petermaccc.bsky.social

In this study we found that very few pt developed MRD positivity on Osi, but on cessation of Osi 17% developed MRD+ and most within 12mo of stopping